Fujian Province Announces 2020 List of Leading Enterprises in Strategic Emerging Industries, with Maxin Ranking Among the Top 100!

Posted by

6 2 月, 2026

On 6 2 月, 2026

Introduction:

On November 20, the ‘2020 Fujian Top 100 Enterprises Release Conference and Fujian Entrepreneurs Forum,’ jointly organized by the Fujian Provincial Federation of Enterprises and Entrepreneurs, Fujian Radio, Film and Television Group, and Fujian Academy of Social Sciences, was grandly held in Ningde City, Fujian Province. The conference released the 2020 Fujian Top 100 Strategic Emerging Industry Enterprises list, which aims to guide enterprises to accelerate the cultivation of new growth drivers, move towards the mid-to-high end of the industrial chain, and support the development of strategic emerging industries in Fujian Province. Maxin, as the only biomedical-related enterprise in Fuzhou, was honored to be included in the ‘Top 100 Strategic Emerging Industry Enterprises.’

2020 Fujian Top 100 Strategic Emerging Enterprises

This year’s list selection primarily evaluates comprehensive indicators such as ‘operating revenue, net profit, total assets, and total tax payments,’ with operating revenue as the standard. The selection includes enterprises of various ownership types, including state-owned, private, and foreign-funded enterprises. The process strictly follows steps such as ‘enterprise self-application, recommendations from municipal enterprise federations and related economic associations or industry associations, and review by an evaluation committee established by the organizers.’ Before the list’s release, it was publicly announced to solicit feedback. Based on the public announcement, social opinions were promptly understood and fully absorbed, and the final list was confirmed after considering multiple factors.

It is reported that the top 100 enterprises in Fujian in 2020 achieved a total operating revenue of 4 trillion yuan. The top 100 manufacturing enterprises and top 100 service enterprises in Fujian achieved 1.5 trillion yuan and 2.9 trillion yuan, respectively. In contrast, the top 100 strategic emerging industry enterprises achieved only 0.2 trillion yuan in operating revenue, indicating significant room for improvement. From the specific list, state-owned, private, foreign-funded, and joint ventures accounted for 22%, 72%, 5%, and 1%, respectively, with private enterprises dominating, highlighting the vitality of Fujian’s private economy. Notably, in this strategic emerging industry list, 33 enterprises in the new-generation information technology sector, 26 in new materials, and 12 in high-end equipment manufacturing were included, accounting for over 70% of the total. However, only 9 enterprises were in the biotechnology sector, representing less than 10%. In the biomedical-related niche market where Maxin operates, only 2 enterprises were included, indicating an urgent need for the industry to gain attention and catch up.

Maxin has been deeply rooted in pathology for nearly thirty years. In recent years, its business expansion has been steady and progressive, with endogenous momentum continuously increasing and development speed accelerating. Its brand recognition and influence within and outside the industry have been steadily rising. As a member of national enterprises, Maxin feels a greater sense of responsibility and mission upon receiving this honor. In the future, we will remain committed to scientific research and innovation, comprehensively promote the localization of core technologies for in vitro diagnostic reagents and instruments, and contribute to the advancement of China’s pathology industry, the prosperity of the social economy, and the health of the people.

发表回复 取消回复

发表回复取消回复